First new PBC treatment in 20 years approved!

The Canadian PBC Society is excited to share that a new treatment option for PBC is on it’s way, thanks to the recent Canadian conditional approval of obeticholic acid, otherwise known as Ocaliva, or OCA. According to a recent release by Intercept Pharmaceuticals, Health Canada has issued a conditional Notice of Compliance for Ocaliva, which is indicated for the treatment of PBC, in combination with URSO, or as monotherapy for those who cannot tolerate URSO.

 

This is the first new treatment for PBC in 20 years. “I’m thrilled that another treatment has finally been approved. I have spoken to so many patients that have been waiting for other treatments to become available because URSO isn’t working for them,” said Gail Wright, Canadian PBC Society President. “Our community is so energized by this news, and we look forward to our members being able to manage their disease more effectively.”

 

We anticipate that patients will be able to receive access to OCA in a number of different ways, including private insurance, provincial pharmacare plans and compassionate support programs. We’ll be happy to provide more details as they come available. Read full press release